Investor FAQs

Below are some of the most frequently asked questions about Biostage:

COMMUNICATIONS AND GENERAL ISSUES:
Will email addresses be changing for the contacts with whom I communicate?

All Biostage employees have been transitioned to a new email address format based on the @biostage.com URL. Our email addresses are based on the first letter of the first name followed by last name @Biostage.com.   So Sam Jenkins would be sjenkins@biostage.com

In addition, for the next few weeks the existing @hartregen.com email addresses that you have used in the past will be forwarded to each persons’ new @biostage.com address, so that they will be assured of receiving your emails during the transition period. 

Should I change the physical location/mailing address to which invoices or shipments are submitted?

No, our physical and mailing address locations are not changing. However, you will need to update your records and correspondence for purchase orders, invoicing, etc. to reflect our new legal name(s) Biostage, Inc.  Please do so as soon as possible but certainly by the end of April 2016.

Where is Biostage’s corporate headquarters?

Biostage’s headquarters will remain at the same location: 84 October Hill Road, Suite 11, Holliston, MA  01746, with the same main phone number 774-233-7300. The Company’s website is www.biostage.com

Will my contract with Harvard Apparatus Regenerative Technology, Inc. need to be revised or recreated?

No. Existing contracts and agreements that reference Harvard Apparatus Regenerative Technology, Inc. legal entities remain in full force before and after the name change, and will be fully honored under Biostage, Inc. We do not anticipate any changes to other contract terms and conditions. Changes to the name within these documents will occur upon renewal only. 

What is Biostage’s fiscal year?

The company’s fiscal year will continue to be January 1 – December 31. 

When was Biostage founded?

Biostage, Inc. was spun-off to shareholders of Harvard Bioscience, Inc. (HBIO) on November 1, 2013. Prior to its spin-off, the Company was a business segment of Harvard Bioscience, Inc. At the time of its spin-off, the Company’s name was Harvard Apparatus Regenerative Technology, Inc.

STOCKHOLDER ISSUES:
Who can I contact about questions regarding my investment in Biostage, Inc. Nasdaq: BSTG (formerly Harvard Apparatus Regenerative Technology, Inc. (HART)

Please feel free to contact our investor relations (IR) team with any questions regarding Biostage, the name change, your investment, etc. – or to have your name added to our investor email distribution list. Our IR team is committed to addressing your questions immediately and to responding to messages or emails in no more than 24 hours.

Our investor relations team’s contact information is as follows:

                Jenene Thomas Communications LLC
                Phone:                (908) 938-1475                           
                e-mail:                jtc@jenenethomascommunications.com

Will I need to turn in my Harvard Apparatus Regenerative Technology (HART) stock to convert my ownership into Biostage shares?

If your shares are in a brokerage account:  If you hold your shares in a brokerage account or retirement account, the conversion of your shares from HART into Biostage shares will happen automatically over the next few days, and you do not need to take any action for this to happen. Name changes are a normal occurrence and the systems are well set up to take care of this, though it might take a few days in certain circumstances. Please contact your broker with any questions about this transfer, as Biostage does not have access information about shares held at brokerage firms.

If your shares are held in certificate form:  If you hold your shares in certificate form, there is nothing you need to do in the near term, because our Transfer Agent and Registrar will adjust their records to reflect the name change and will note your HART share certificates now reflect an ownership interest (same number of shares) in Biostage shares. Eventually you will have to submit your share certificate to the Transfer Agent and Registrar – Computershare Limited (contact info below) to receive a new certificate or to set up an account with them in which your shares can be held electronically by Computershare in the new Biostage, Inc. name. 

What market does Biostage trade on?

Biostage will trade on the Nasdaq Capital Market – the same market on which HART traded - under the ticker symbol “BSTG,” starting with the commencement of regular trading on Friday, April 1, 2016. Note that there can be delays or time lags in the updating of various securities information databases due to their systems and processes, so it is possible that the Company name or other information will not be completely or accurately updated by certain databases in the first few days of trading.  This should not be a cause for concern, but if you see any seemingly erroneous information, you can report it to our investor relations team via the email jtc@jenenethomascommunications.com or by calling them at (908) 938-1475.

Do I have the same number of Biostage shares as I had HART shares?

Yes, the number of shares you own will not be affected by the company’s name change.

What is Biostage’s Common Stock CUSIP (identification) number?

Effective immediately Biostage’s common stock CUSIP is 09074M103
Previously Harvard Apparatus Regenerative Technology’s CUSIP for common stock was 41690A106

Who is Biostage’s transfer agent and registrar and Whom do I contact with questions about my stock certificates?

Biostage, Inc.’s transfer agent and registrar is Computershare Limited Computershare can be reached as follows:

Phone: 1 800 522 6645 or 1 201 680 6578
Online: https://www-us.computershare.com/Investor/Contact
Mail: Regular Mail Address By Overnight Delivery
  P.O. BOX 30170 211 Quality Circle, Suite 210
  College Station, TX 77842 College Station, TX 77845
  USA USA
How can I view documents Biostage, Inc. has filed with the Securities & Exchange Commission (SEC)?

To access Biostage’s filings with the SEC, please visit:
http://ir.biostage.com/financial-filings

How can I request additional information or materials from the company?

Our investor relations team’s contact information is as follows:

                Jenene Thomas Communications LLC – Investor Relations
                Phone:                (908) 938-1475
                e-mail:                jtc@jenenethomascommunications.com

 


print email